Abstract
Conventional therapies for pancreatic cancer involve limitations. Targeted therapy and immunotherapy are partially effective; however, they often cause adverse reactions and toxic side effects, sometimes necessitating treatment discontinuation. Early identification, diagnosis, and management of these treatment-related complications are crucial for ensuring patient safety while maintaining optimal therapeutic efficacy. This narrative review summarizes common adverse reactions to targeted therapy and immunotherapy for pancreatic cancer as well as corresponding management strategies.